Entrada Therapeutics Reports First Quarter 2026 Financial Results
Entrada Therapeutics reported positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study of ENTR-601-44 in DMD, showing statistically significant improvement in Time to Rise velocity and a favorable safety profile. The company confirmed cash runway into Q3 2027 with $254.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
Key figures
- Revenue
- 875000
- Guidance
- Cash runway expected into Q3 2027
- Drug Name
- ENTR-601-44
- Net loss
- 39700000
- Cash runway
- Q3 2027
- Ga expenses
- 10100000
- Rd expenses
- 33100000
- Phase Of Trial
- Phase 1/2
- Cash position
- 254900000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.